Intra-Cellular Therapies
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2002-01-01
- Employees
- 610
- Market Cap
- $7.8B
- Introduction
Intra-Cellular Therapies, Inc. operates as a biopharmaceutical company. It focuses on the discovery and clinical development of small molecule drugs that address underserved medical needs in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms within the central nervous system, or CNS. The firm’s lead product candidate, ITI-007, is in clinical development as a first-in-class treatment for schizophrenia. It also includes pre-clinical programs that are focused on advancing drug candidates for the treatment of cognitive dysfunction, in both schizophrenia and Alzheimer's disease and for disease modification and the treatment of neurodegenerative disorders, including Alzheimer's disease. The company was founded by Paul Greengard and Sharon Mates in 2002 and is headquartered in New York, NY.
ITI-007 for the Treatment of Agitation in Patients With Dementia, Including Alzheimer's Disease
- Conditions
- Agitation in Dementia, Including Alzheimer's Disease
- Interventions
- Drug: Placebo
- First Posted Date
- 2016-06-29
- Last Posted Date
- 2021-06-29
- Lead Sponsor
- Intra-Cellular Therapies, Inc.
- Target Recruit Count
- 177
- Registration Number
- NCT02817906
Clinical Trial Evaluating ITI-007 as an Adjunctive Therapy to Lithium or Valproate for the Treatment of Bipolar Depression
- First Posted Date
- 2015-11-09
- Last Posted Date
- 2023-05-17
- Lead Sponsor
- Intra-Cellular Therapies, Inc.
- Target Recruit Count
- 529
- Registration Number
- NCT02600507
- Locations
- 🇺🇦
Clinical Site, Vinnytsia, Ukraine
Clinical Trial Evaluating ITI-007 (Lumateperone) as a Monotherapy for the Treatment of Bipolar Depression
- Conditions
- Bipolar Depression
- Interventions
- Drug: PlaceboDrug: ITI-007 (Lumateperone)
- First Posted Date
- 2015-11-09
- Last Posted Date
- 2021-04-14
- Lead Sponsor
- Intra-Cellular Therapies, Inc.
- Target Recruit Count
- 554
- Registration Number
- NCT02600494
- Locations
- 🇺🇸
Clinical Site, Everett, Washington, United States
A Trial to Assess the Antipsychotic Efficacy of ITI-007 Over 6 Weeks of Treatment
- First Posted Date
- 2015-06-11
- Last Posted Date
- 2017-11-14
- Lead Sponsor
- Intra-Cellular Therapies, Inc.
- Target Recruit Count
- 696
- Registration Number
- NCT02469155
- Locations
- 🇺🇸
Clinical Site, Long Beach, California, United States
Receptor Occupancy of ITI-007 Using Positron Emission Tomography (PET) in Patients With Stable Schizophrenia
- First Posted Date
- 2014-11-11
- Last Posted Date
- 2017-03-10
- Lead Sponsor
- Intra-Cellular Therapies, Inc.
- Target Recruit Count
- 14
- Registration Number
- NCT02288845
- Locations
- 🇺🇸
Johns Hopkins Medical Institutions, Baltimore, Maryland, United States
A Trial to Assess the Antipsychotic Efficacy of ITI-007
- First Posted Date
- 2014-11-04
- Last Posted Date
- 2017-03-10
- Lead Sponsor
- Intra-Cellular Therapies, Inc.
- Target Recruit Count
- 450
- Registration Number
- NCT02282761
- Locations
- 🇺🇸
Clinical Site, Long Beach, California, United States
Study of ITI-007 in Healthy Geriatric Volunteers and in Geriatric Patients With Dementia
- First Posted Date
- 2014-03-05
- Last Posted Date
- 2017-11-17
- Lead Sponsor
- Intra-Cellular Therapies, Inc.
- Target Recruit Count
- 35
- Registration Number
- NCT02078310
Study of a Novel Antipsychotic ITI-007 in Schizophrenia
- First Posted Date
- 2011-12-26
- Last Posted Date
- 2017-03-10
- Lead Sponsor
- Intra-Cellular Therapies, Inc.
- Target Recruit Count
- 335
- Registration Number
- NCT01499563